Abstract
We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m–2 week–1 and leucovorin 500 mg m–2 week–1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify the possible mechanism underlying the improved activity of HDFL compared with conventional 5-FU regimens, we conducted in vitro studies examining the effect of these regimens on the differential regulation of thymidylate synthase (TS) in NCI-N87, a human gastric cancer cell line. The expected serum concentrations of 5-FU are 100–200 mM (lasting for less than 30 min) and 5–10 mM (lasting for 24 h) for the conventional 5-FU regimens (bolus injection or short intravenous infusion of 5-FU 370–500 mg m–2) and the HDFL regimens, respectively. Western blot analysis revealed that 24-h exposure of NCI-N87 to 2.5–10.0 mM of 5-FU resulted in a dose-dependent depletion of free TS, lasting for more than 24 h. In contrast, 30-min exposure of NCI-N87 to 200 mM of 5-FU resulted in a less than 12-h depletion of free TS. Moreover, 24-h exposure to 5-FU resulted in a higher S-phase blockade and enhanced cytotoxicity. In both modes of 5-FU treatment, the initial rapid depletion of free TS was accompanied by a rapid increment of a higher-molecular-weight TS molecule, suggesting that rapid formation of the ternary complex was the key mechanism of 5-FU action during this period. Northern blot analysis showed that the steady-state mRNA of TS was not affected by either of the schedules. We conclude that 24-h exposure of gastric cancer cells to low concentration of 5-FU resulted in better suppression of free TS, a higher degree of S-phase blockade, and enhanced cytotoxicity compared to 30-min exposure to high concentration of 5-FU. These in vitro results may help explain the improved clinical efficacy of HDFL regimens compared to conventional 5-FU regimens. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
árdalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Lepaspi A, Waldman S, Morrell L, Feun L, Savaraj N and Livingstone A (1991 A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625–630
Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC and Bertino JR (1998 Role of E2F-1 in chemosensitivity. Cancer Res 58: 4292–4296
Beerblock K, Rinaldi Y, Andre T, Louvet C, Raymond E, Tournigand C, Carola E, Favre R, de Gramont A and Krulik M (1997 Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d’Etude et de Recherche sur les Cancers de l’Ovaire et Digestifs (GERCOD). Cancer 79: 1100–1105
Cheng AL, Yeh KH, Lin JT, Hsu C and Liu MY (1998 Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) – a very effective regimen with good patient compliance for advanced gastric cancer. Anticancer Res 18: 1267–1272
Chomczynski P and Sacchi N (1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159
Chu E and Allegra CJ (1996 The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul 36: 143–163
Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC and Allegra CJ 1991a Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136–143
Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S and Allegra CJ 1991b Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 88: 8977–8981
de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E and Bedenne L (1997 Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808–815
de Gramont A, Louvet C, Andre T, Tournigand C and Krulik M (1998 A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d’Etude et de Recherche sur les Cancers de l’Ovaire et Digestifs (GERCOD). Eur J Cancer 34: 619–626
Dolnick BJ, Black AR, Winkler PM, Schindler K and Hsueh CT (1996 rTS gene expression is associated with altered cell sensitivity to thymidylate synthase inhibitors. Advan Enzyme Regul 36: 165–180
Fraile RJ, Baker LH, Buroker TR, Horwitz J and Vaitkevicius VK (1980 Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40: 2223–2228
Grem JL (1996 5-Fluoropyrimidines. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner BA, Longo DL (eds), pp 149–212, Philadelphia, Lippincott-Raven Publishers
Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, Sorensen JM, Sartor O, Kramer BS, Goldstein LJ, Gay LM, Caubo KM, Goldspiel B and Allegra CJ (1991 A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 9: 1811–1820
Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC and Cheng AL (1997 Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: an effective and low-toxic regimen for patients with poor general condition. Oncology 54: 275–280
Johnston PG, Liang CM, Henry S, Chabner BA and Allegra CJ (1991 Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51: 6668–6676
Johnston PG, Drake JC, Trepel J and Allegra CJ (1992 Immunological quantitation of thymidylate synthase using monoclonal antibody TS106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306–4312
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ (1994 The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647
Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407–1412
Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B and Schmoll HJ (1998 Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418–426
Laemmli UK (1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685
Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J and Garcia Y (1996 Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176–182
Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM and Bertino JR (1995 Lack of functional retinoblastinoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 92: 10436–10440
Meta-analysis Group In Cancer (1998 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308
Navelgund LG, Rossana C, Muench AJ and Johnson LF (1980 Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 255: 7386–7390
Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S and Pinedo HM (1994 Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12: 2035–2042
Tsujinaka T, Kido Y, Shiozaki H, Iijima S, Homma T and Sakaue M (1992 Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 70: 2761–2765
Vanhoefer U, Wilke H, Weh HJ, Clemens M, Harstrick A, Stahl M, Hossfeld DK and Seeber S (1994 Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 5: 850–851
Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Subert R, Kriebel R and Hossfeld DK (1994 Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5: 233–237
Wilke H, Klaassen U, Achterrath W, Losch M, Vanhoefer U, Hayungs J, Harstrick A, Stahl M, Eberhardt W, Becher R and Seeber S (1996 Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7: 55–58
Yeh KH and Cheng AL (1994 An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin. J Clin Oncol 12: 875–876
Yeh KH and Cheng AL (1998 Gastric cancer associated with acute disseminated intravascular coagulation – successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. Br J Haematol 100: 769–772
Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH and Chen YC (1997 A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 17: 3867–3872
Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC and Cheng AL 1998a High expression of thymidylate synthase is associated with drug resistance of gastric cancers to high-dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626–1631
Yeh KH, Chen YC, Yeh SH, Chen JP, Lin JT and Cheng AL 1998b Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19) – possible clinical significance in advanced gastric cancer. Anticancer Res 18: 1283–1286
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Yeh, KH., Yeh, SH., Hsu, CH. et al. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 83, 1510–1515 (2000). https://doi.org/10.1054/bjoc.2000.1456
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1456
Keywords
This article is cited by
-
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
BMC Cancer (2020)
-
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression
Gastric Cancer (2012)
-
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
BMC Cancer (2008)
-
Bimonthly 24 h Infusion of High-Dose 5-Fluorouracil vs EAP Regimen in Patients with Advanced Gastric Cancer
Medical Oncology (2008)
-
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
British Journal of Cancer (2005)